{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T07:00:04Z","timestamp":1791442804347,"version":"4.3.3"},"reference-count":74,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Sanofi"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Gaucher disease (GD) is a lysosomal storage disorder caused by mutations in the glucocerebrosidase gene (GBA1), leading to acid \u03b2-glucosidase deficiency and the accumulation of glucosylceramide-derived glycosphingolipids. Its three phenotypes (non-neuronopathic, acute neuronopathic, and chronic neuronopathic) have variable clinical presentations including hepatosplenomegaly, cytopenia, bone disease, and neurological involvement. Early diagnosis and treatment are critical for improving outcomes, but GD is under-recognized due to non-specific symptoms and limited access to appropriate diagnostic testing. Glucosylsphingosine (lyso-Gb1), a deacylated metabolite of glucosylceramide, has been identified as a candidate biomarker for diagnosis and monitoring. This narrative review examines the role of biomarkers in GD, focusing on lyso-Gb1 as a potential diagnostic and prognostic biomarker. Lyso-Gb1 is markedly elevated in GD patients and correlates with disease burden, severity, and response to therapy. It is detectable in plasma and dried blood spots, making it suitable for newborn screening, diagnosis, and monitoring. Lyso-Gb1 is a sensitive and specific biomarker for GD, facilitating early detection, guiding treatment decisions, and enabling personalized disease management. Lyso-Gb1 levels reflect substrate accumulation and therapeutic response more reliably than other biomarkers such as chitotriosidase or CCL18. Ongoing research aims to refine diagnostic thresholds and integrate lyso-Gb1 monitoring into routine clinical practice for optimal patient outcomes.<\/jats:p>","DOI":"10.3390\/ijms27041705","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T11:16:38Z","timestamp":1770722198000},"page":"1705","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Glucosylsphingosine (Lyso-Gb1): An Update on Its Use as a Biomarker in Gaucher Disease"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7504-6407","authenticated-orcid":false,"given":"Francesca","family":"Carubbi","sequence":"first","affiliation":[{"name":"Unit of Internal Metabolic Medicine, University of Modena and Reggio Emilia, Baggiovara University Hospital AOU of Modena, 41126 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5849-7377","authenticated-orcid":false,"given":"Silvia","family":"Linari","sequence":"additional","affiliation":[{"name":"Center for Bleeding Disorders and Coagulation, Careggi University Hospital, 50134 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8894-350X","authenticated-orcid":false,"given":"Marco","family":"Spada","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Torino, 10126 Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(08)61522-6","article-title":"Phenotype, diagnosis, and treatment of Gaucher\u2019s disease","volume":"372","author":"Grabowski","year":"2008","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/humu.20676","article-title":"Gaucher disease: Mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA)","volume":"29","author":"Hruska","year":"2008","journal-title":"Hum. Mutat."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/10245332.2016.1240391","article-title":"Gaucher disease epidemiology and natural history: A comprehensive review of the literature","volume":"22","author":"Nalysnyk","year":"2017","journal-title":"Hematology"},{"key":"ref_4","unstructured":"Stone, W.L., Basit, H., Mukkamalla, S.K.R., and Master, S.R. (2024). Gaucher Disease. StatPearls, StatPearls Publishing LLC."},{"key":"ref_5","first-page":"3","article-title":"Pathophysiology, clinical features, and natural history of Gaucher disease","volume":"10","author":"Weinreb","year":"2012","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1182\/blood-2011-05-352971","article-title":"Elevated plasma glucosylsphingosine in Gaucher disease: Relation to phenotype, storage cell markers, and therapeutic response","volume":"118","author":"Dekker","year":"2011","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ymgme.2021.12.009","article-title":"Screening, patient identification, evaluation, and treatment in patients with Gaucher disease: Results from a Delphi consensus","volume":"135","author":"Kishnani","year":"2022","journal-title":"Mol. Genet. Metab."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Dinur, T., Bauer, P., Beetz, C., Kramp, G., Cozma, C., Iura\u0219cu, M.I., Becker-Cohen, M., Istaiti, M., Rolfs, A., and Zimran, A. (2022). Gaucher disease diagnosis using Lyso-Gb1 on dry blood spot samples: Time to change the paradigm?. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031627"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Malinov\u00e1, V., Poup\u011btov\u00e1, H., \u0158eboun, M., Dvo\u0159\u00e1kov\u00e1, L., Reichmannov\u00e1, S., \u0160vandov\u00e1, I., Murga\u0161ov\u00e1, L., Kasper, D.C., and Magner, M. (2023). Long-term evaluation of biomarkers in the Czech cohort of Gaucher patients. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241914440"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/MPH.0000000000002506","article-title":"Global epidemiology of Gaucher disease: An updated systematic review and meta-analysis","volume":"45","author":"Wang","year":"2023","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Castillon, G., Chang, S.C., and Moride, Y. (2022). Global incidence and prevalence of Gaucher disease: A targeted literature review. J. Clin. Med., 12.","DOI":"10.3390\/jcm12010085"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ymgme.2016.11.006","article-title":"Gaucher disease: Progress and ongoing challenges","volume":"120","author":"Mistry","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"107023","DOI":"10.1016\/j.parkreldis.2024.107023","article-title":"Increased glucosylsphingosine levels and Gaucher disease in GBA1-associated Parkinson\u2019s disease","volume":"124","author":"Marano","year":"2024","journal-title":"Park. Relat. Disord."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.cca.2021.07.017","article-title":"Levels of Lyso GL-1 in Gaucher and Lyso GL-3 in Fabry patients from India: Diagnostic aids for these lysosomal storage disorders","volume":"521","author":"Verma","year":"2021","journal-title":"Clin. Chim. Acta"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.bcmd.2016.10.008","article-title":"Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease","volume":"68","author":"Biegstraaten","year":"2018","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/17446651.2018.1445524","article-title":"Recent advances in the diagnosis and management of Gaucher disease","volume":"13","author":"Gary","year":"2018","journal-title":"Expert Rev. Endocrinol. Metab."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1080\/14656566.2021.1902989","article-title":"Current and emerging pharmacotherapy for Gaucher disease in pediatric populations","volume":"22","author":"Sam","year":"2021","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_18","first-page":"Cd010324","article-title":"Enzyme replacement and substrate reduction therapy for Gaucher disease","volume":"2015","author":"Shemesh","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Stirnemann, J., Belmatoug, N., Camou, F., Serratrice, C., Froissart, R., Caillaud, C., Levade, T., Astudillo, L., Serratrice, J., and Brassier, A. (2017). A review of Gaucher disease pathophysiology, clinical presentation and treatments. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18020441"},{"key":"ref_20","first-page":"7","article-title":"Genetics and diagnosis of Gaucher disease","volume":"10","author":"Mistry","year":"2012","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Biomarkers Definitions Working Group (2001). Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin. Pharmacol. Ther., 69, 89\u201395.","DOI":"10.1067\/mcp.2001.113989"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"101242","DOI":"10.1016\/j.gim.2024.101242","article-title":"Biomarker testing for lysosomal diseases: A technical standard of the American College of Medical Genetics and Genomics (ACMG)","volume":"27","author":"Stiles","year":"2025","journal-title":"Genet. Med."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Curado, F., R\u00f6sner, S., Zielke, S., Westphal, G., Grittner, U., Skrahina, V., Alasel, M., Malik, A.M., Beetz, C., and B\u00f6ttcher, T. (2023). Insights into the value of Lyso-Gb1 as a predictive biomarker in treatment-na\u00efve patients with Gaucher disease type 1 in the LYSO-PROOF study. Diagnostics, 13.","DOI":"10.3390\/diagnostics13172812"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Revel-Vilk, S., Fuller, M., and Zimran, A. (2020). Value of glucosylsphingosine (Lyso-Gb1) as a biomarker in Gaucher disease: A systematic literature review. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21197159"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1186\/s13023-022-02573-6","article-title":"Patient centered guidelines for the laboratory diagnosis of Gaucher disease type 1","volume":"17","author":"Dardis","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/ajh.21721","article-title":"Hyperferritinemia and iron overload in type 1 Gaucher disease","volume":"85","author":"Stein","year":"2010","journal-title":"Am. J. Hematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.cbpa.2019.10.006","article-title":"Glycosphingolipids and lysosomal storage disorders as illustrated by gaucher disease","volume":"53","author":"Aerts","year":"2019","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1172\/JCI117084","article-title":"Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease","volume":"93","author":"Hollak","year":"1994","journal-title":"J. Clin. Investig."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13023-023-02623-7","article-title":"Glucosylsphingosine (Lyso-Gb1) as a reliable biomarker in Gaucher disease: A narrative review","volume":"18","author":"Giuffrida","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Rolfs, A., Giese, A.K., Grittner, U., Mascher, D., Elstein, D., Zimran, A., B\u00f6ttcher, T., Lukas, J., H\u00fcbner, R., and G\u00f6lnitz, U. (2013). Glucosylsphingosine is a highly sensitive and specific biomarker for primary diagnostic and follow-up monitoring in Gaucher disease in a non-Jewish, Caucasian cohort of Gaucher disease patients. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0079732"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.1111\/j.1742-4658.2009.07259.x","article-title":"Common G102S polymorphism in chitotriosidase differentially affects activity towards 4-methylumbelliferyl substrates","volume":"276","author":"Bussink","year":"2009","journal-title":"FEBS J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"25680","DOI":"10.1074\/jbc.273.40.25680","article-title":"The human chitotriosidase gene. Nature of inherited enzyme deficiency","volume":"273","author":"Boot","year":"1998","journal-title":"J. Biol. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/humu.20524","article-title":"Type 1 Gaucher disease: Null and hypomorphic novel chitotriosidase mutations-implications for diagnosis and therapeutic monitoring","volume":"28","author":"Grace","year":"2007","journal-title":"Hum. Mutat."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.bcmd.2007.06.013","article-title":"Human chitotriosidase polymorphisms G354R and A442V associated with reduced enzyme activity","volume":"39","author":"Lee","year":"2007","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_35","first-page":"72","article-title":"Gaucher disease: The metabolic defect, pathophysiology, phenotypes and natural history","volume":"12","author":"Baris","year":"2014","journal-title":"Pediatr. Endocrinol. Rev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S0022-2275(20)36768-7","article-title":"Isolation and characterization of glucosylsphingosine from Gaucher\u2019s spleen","volume":"15","author":"Raghavan","year":"1974","journal-title":"J. Lipid Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1471-4159.1982.tb07950.x","article-title":"Accumulation of glucosylceramide and glucosylsphingosine (psychosine) in cerebrum and cerebellum in infantile and juvenile Gaucher disease","volume":"39","author":"Nilsson","year":"1982","journal-title":"J. Neurochem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S1096-7192(02)00117-8","article-title":"Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: Correlation with phenotype and genotype","volume":"76","author":"Orvisky","year":"2002","journal-title":"Mol. Genet. Metab."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.chroma.2017.10.038","article-title":"Optimization of ultra-high pressure liquid chromatography\u2014Tandem mass spectrometry determination in plasma and red blood cells of four sphingolipids and their evaluation as biomarker candidates of Gaucher\u2019s disease","volume":"1525","author":"Chipeaux","year":"2017","journal-title":"J. Chromatogr. A"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"9726","DOI":"10.1111\/jcmm.15534","article-title":"Effects of sphingolipids overload on red blood cell properties in Gaucher disease","volume":"24","author":"Dupuis","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/1873-3468.12104","article-title":"Lysosomal glycosphingolipid catabolism by acid ceramidase: Formation of glycosphingoid bases during deficiency of glycosidases","volume":"590","author":"Ferraz","year":"2016","journal-title":"FEBS Lett."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/ajh.24491","article-title":"Glucosylsphingosine is a key biomarker of Gaucher disease","volume":"91","author":"Murugesan","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Dubiela, P., Szymanska-Rozek, P., Eljaszewicz, A., Lipinski, P., Hasinski, P., Giersz, D., Walewska, A., Tynecka, M., Moniuszko, M., and Tylki-Szymanska, A. (2023). Alpha-Synuclein mRNA Level Found Dependent on L444P Variant in Carriers and Gaucher Disease Patients on Enzyme Replacement Therapy. Biomolecules, 13.","DOI":"10.3390\/biom13040644"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"9617","DOI":"10.1523\/JNEUROSCI.1525-17.2017","article-title":"Glucosylsphingosine Promotes \u03b1-Synuclein Pathology in Mutant GBA-Associated Parkinson\u2019s Disease","volume":"37","author":"Taguchi","year":"2017","journal-title":"J. Neurosci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"19473","DOI":"10.1073\/pnas.1003308107","article-title":"Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage","volume":"107","author":"Mistry","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"10018","DOI":"10.1073\/pnas.1200941109","article-title":"Gaucher disease gene GBA functions in immune regulation","volume":"109","author":"Liu","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1073\/pnas.1400768111","article-title":"Glucocerebrosidase 2 gene deletion rescues type 1 Gaucher disease","volume":"111","author":"Mistry","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1182\/blood-2014-09-600270","article-title":"Type II NKT-TFH cells against Gaucher lipids regulate B-cell immunity and inflammation","volume":"125","author":"Nair","year":"2015","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa1508808","article-title":"Clonal immunoglobulin against lysolipids in the origin of myeloma","volume":"374","author":"Nair","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/path.4452","article-title":"Inhibition of UDP-glucosylceramide synthase in mice prevents Gaucher disease-associated B-cell malignancy","volume":"235","author":"Pavlova","year":"2015","journal-title":"J. Pathol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ymgme.2020.01.009","article-title":"Glucosylsphingosine but not Saposin C, is the target antigen in Gaucher disease-associated gammopathy","volume":"129","author":"Nair","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Szyma\u0144ska-Ro\u017cek, P., Lipi\u0144ski, P., Kleinotiene, G., Dubiela, P., and Tylki-Szyma\u0144ska, A. (2024). Effects of GBA1 variants and prenatal exposition on the glucosylsphingosine (Lyso-Gb1) levels in Gaucher disease carriers. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252212021"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Gragnaniello, V., Cazzorla, C., Gueraldi, D., Puma, A., Loro, C., Porcu, E., Stornaiuolo, M., Miglioranza, P., Salviati, L., and Burlina, A.P. (2023). Light and shadows in newborn screening for lysosomal storage disorders: Eight years of experience in Northeast Italy. Int. J. Neonatal Screen., 10.","DOI":"10.20944\/preprints202311.0727.v1"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1515\/cclm-2019-0949","article-title":"LC-MS\/MS analysis of plasma glucosylsphingosine as a biomarker for diagnosis and follow-up monitoring in Gaucher disease in the Spanish population","volume":"58","author":"Cebolla","year":"2020","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Dinur, T., Grittner, U., Revel-Vilk, S., Becker-Cohen, M., Istaiti, M., Cozma, C., Rolfs, A., and Zimran, A. (2021). Impact of long-term enzyme replacement therapy on glucosylsphingosine (Lyso-Gb1) values in patients with type 1 Gaucher disease: Statistical models for comparing three enzymatic formulations. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22147699"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.ymgme.2018.02.004","article-title":"Plasma chitotriosidase activity versus plasma glucosylsphingosine in wide spectrum of Gaucher disease phenotypes\u2014A statistical insight","volume":"123","author":"Hasinski","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Dubiela, P., Szymanska-Rozek, P., Hasinski, P., Lipinski, P., Kleinotiene, G., Giersz, D., and Tylki-Szymanska, A. (2024). Long- and short-term glucosphingosine (lyso-Gb1) dynamics in Gaucher patients undergoing enzyme replacement therapy. Biomolecules, 14.","DOI":"10.3390\/biom14070842"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"107736","DOI":"10.1016\/j.ymgme.2023.107736","article-title":"Treatment-naive and post-treatment glucosylsphingosine (lyso-GL1) levels in a cohort of pediatric patients with Gaucher disease","volume":"141","author":"Rasmussen","year":"2024","journal-title":"Mol. Genet. Metab."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Hurvitz, N., Dinur, T., Becker-Cohen, M., Cozma, C., Hovakimyan, M., Oppermann, S., Demuth, L., Rolfs, A., Abramov, A., and Zimran, A. (2019). Glucosylsphingosine (lyso-Gb1) as a biomarker for monitoring treated and untreated children with Gaucher disease. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20123033"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"107527","DOI":"10.1016\/j.ymgme.2023.107527","article-title":"Plasma glucosylsphingosine correlations with baseline disease burden and response to eliglustat in two clinical trials of previously untreated adults with Gaucher disease type 1","volume":"138","author":"Peterschmitt","year":"2023","journal-title":"Mol. Genet. Metab."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Dinur, T., Zimran, A., Becker-Cohen, M., Arkadir, D., Cozma, C., Hovakimyan, M., Oppermann, S., Demuth, L., Rolfs, A., and Revel-Vilk, S. (2019). Long term follow-up of 103 untreated adult patients with type 1 Gaucher disease. J. Clin. Med., 8.","DOI":"10.3390\/jcm8101662"},{"key":"ref_62","first-page":"100729","article-title":"The role of glucosylsphingosine as an early indicator of disease progression in early symptomatic type 1 Gaucher disease","volume":"27","author":"Stiles","year":"2021","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"E140","DOI":"10.1002\/ajh.25074","article-title":"Glucosylsphingosine is a reliable response biomarker in Gaucher disease","volume":"93","author":"Arkadir","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Cozma, C., Cullufi, P., Kramp, G., Hovakimyan, M., Velmishi, V., Gjikopulli, A., Tomori, S., Fischer, S., Oppermann, S., and Grittner, U. (2020). Treatment efficiency in Gaucher patients can reliably be monitored by quantification of Lyso-gb1 concentrations in dried blood spots. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21134577"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/jimd.12192","article-title":"Expanding the clinical utility of glucosylsphingosine for Gaucher disease","volume":"43","author":"Saville","year":"2020","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1186\/s13023-022-02549-6","article-title":"An observational study to investigate the relationship between plasma glucosylsphingosine (lyso-Gb1) concentration and treatment outcomes of patients with Gaucher disease in Japan","volume":"17","author":"Ida","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Dinur, T., Bauer, P., Beetz, C., Cozma, C., Becker-Cohen, M., Istaiti, M., Rolfs, A., Skrahina, V., Zimran, A., and Revel-Vilk, S. (2023). Contribution of glucosylsphingosine (Lyso-Gb1) to treatment decisions in patients with Gaucher disease. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24043945"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"223","DOI":"10.4155\/bio-2021-0242","article-title":"Quantitation of a plasma biomarker profile for the early detection of Gaucher disease type 1 patients","volume":"14","author":"Menkovic","year":"2022","journal-title":"Bioanalysis"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"248","DOI":"10.5603\/ahp.101026","article-title":"Lyso-Gb1\u2014A highly specific biomarker for Gaucher disease","volume":"56","year":"2025","journal-title":"Acta Haematol. Pol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.clinbiochem.2020.10.011","article-title":"Detection of glucosylsphingosine in dried blood spots for diagnosis of Gaucher disease by LC-MS\/MS","volume":"87","author":"Tang","year":"2021","journal-title":"Clin. Biochem."},{"key":"ref_71","first-page":"100798","article-title":"Incremental biomarker and clinical outcomes after switch from enzyme therapy to eliglustat substrate reduction therapy in Gaucher disease","volume":"29","author":"Kleytman","year":"2021","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/ajh.25300","article-title":"Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trial","volume":"94","author":"Lukina","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/ajh.26276","article-title":"Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results","volume":"96","author":"Mistry","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13023-016-0413-3","article-title":"Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients","volume":"11","author":"Smid","year":"2016","journal-title":"Orphanet J. Rare Dis."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/4\/1705\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T05:29:52Z","timestamp":1770874192000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/4\/1705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":74,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["ijms27041705"],"URL":"https:\/\/doi.org\/10.3390\/ijms27041705","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]}}}